Opioid-Based Haptens: Development of Immunotherapy.

Area of Science:

• Pharmacology
• Immunology
• Addiction Medicine

Background:

• Extensive preclinical research targets substance use disorders (SUDs) from opioids, nicotine, and cocaine.
• Small drug molecules like morphine and fentanyl derivatives are not immunogenic but can be conjugated to carrier proteins as haptens.
• Antibody production against hapten-carrier conjugates enables specific reactions with the parent drug.

Purpose of the Study:

• To review the design of opioid haptens for vaccine development.
• To discuss the development and application of opioid radioimmunoassays.
• To summarize the outcomes of immunotherapy for opioid use disorders (OUDs).

Main Methods:

• Conjugation of opioid derivatives (haptens) to carrier proteins.
• Immunization of animals with hapten-carrier conjugates to produce specific antibodies.
• Development of immunoassays, such as radioimmunoassays, for drug detection.

Main Results:

• The attachment site of haptens influences antibody specificity.
• Immunoassays utilize drug-specific antibodies to detect drugs by inhibiting reactions.
• Pharmacological studies led to the development of vaccines for OUD treatment.

Conclusions:

• Immunotherapy for opioid addiction involves anti-drug vaccines composed of haptens, carrier proteins, and adjuvants.
• Vaccine design, particularly hapten modification, is crucial for effective immunotherapy.
• This review highlights progress in hapten design, assay development, and immunotherapy for OUDs.